Resistance of mammalian tumour cells toward pyrimidine analogues. A review.
D000818:Animals; D000963:Antimetabolites / Q000627:therapeutic use*; D001374:Azacitidine / Q000627:therapeutic use; D001380:Azauridine / Q000627:therapeutic use; D001976:Bromouracil / Q000627:therapeutic use; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy; D002460:Cell Line; D006224:Cricetinae; D003561:Cytarabine / Q000627:therapeutic use; D003841:Deoxycytidine; D004351:Drug Resistance; D005472:Fluorouracil / Q000627:therapeutic use; D005815:Genetic Code; D007942:Leukemia, Experimental / Q000188:drug therapy; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D012515:Mast-Cell Sarcoma / Q000188:drug therapy; D051379:Mice; D009154:Mutation; D009374:Neoplasms, Experimental / Q000188:drug therapy* / Q000201:enzymology; D009858:Oncogenic Viruses / Q000166:cytology; D010770:Phosphotransferases / Q000378:metabolism; D011743:Pyrimidines / Q000627:therapeutic use*; D012513:Sarcoma, Experimental / Q000188:drug therapy; D012641:Selection, Genetic; D013937:Thymidine Kinase / Q000378:metabolism; D014498:Uracil / Q000031:analogs & derivatives / Q000627:therapeutic use; D014779:Virus Replication
D000963:Antimetabolites; D011743:Pyrimidines; D003561:Cytarabine; D003841:Deoxycytidine; D001976:Bromouracil; D014498:Uracil; D001380:Azauridine; D010770:Phosphotransferases; D013937:Thymidine Kinase; D001374:Azacitidine; D005472:Fluorouracil